It seems harmless enough, a bottle of biotin gummies from the pharmacy shelf, marketed as a solution for thinning hair and brittle nails. Social media is full of before-and-after photos. Nutrafol and Viviscal line the shelves of health food stores. And for cancer patients navigating the emotionally crushing experience of chemotherapy-related hair loss, the appeal of a simple, inexpensive supplement is entirely understandable.
But a clinical commentary published in JCO Oncology Practice in September 2025 is raising a serious alarm not about whether biotin promotes hair growth (the evidence there is weak), but about something far more consequential: biotin supplements can skew the blood test results that doctors rely on to monitor cancer progression and guide treatment decisions.
This is not a theoretical concern. It is a documented biochemical interaction, and the consequences of delayed treatment, misdiagnosis, and masked cancer recurrence are genuinely dangerous.
Why Cancer Patients Turn to Biotin
Hair loss caused by chemotherapy has been ranked by patients themselves as one of the most emotionally devastating aspects of cancer treatment. In surveys of breast cancer survivors, hair loss and thinning were the most severe symptoms reported during the first year after diagnosis. In another survey of patients with breast cancer, more than half identified hair loss as the single most emotionally distressing part of chemotherapy, ranking it above nausea, fatigue, and pain.
Given those feelings, it makes complete sense that patients look for solutions. Biotin supplements, also called vitamin B7, are heavily marketed for hair and nail health, are inexpensive, are available without prescription, and feel empowering in a situation where patients often feel they have very little control.
What makes the situation more concerning is a 2024 survey of cancer patients in online support communities, which found that oral supplements were the most commonly tried treatment for chemotherapy-related hair loss, more popular than any topical product. And critically, only 6% of patients reported discussing their use of hair and nail supplements with their oncologist or dermatologist.
That communication gap is where the real danger lies.
The Science Behind the Problem: What Biotin Actually Does in Your Blood
To understand why biotin interferes with lab tests, it helps to know how many modern blood tests work at the molecular level.
A large number of clinical immunoassays, including those that measure hormone levels, cancer markers, and thyroid function, rely on a highly specific biochemical interaction between a molecule called streptavidin and biotin (also called the streptavidin-biotin binding system). This interaction is one of the strongest non-covalent bonds in biology, and laboratories use it to anchor detection molecules to testing surfaces.
When you take large doses of supplemental biotin, the vitamin enters your bloodstream in concentrations far higher than what your body produces naturally. Once there, the excess biotin competes directly with the detection system inside the test. It floods the streptavidin-coated surfaces before the real biomarkers can be properly captured and measured.
The result is that some test results come back falsely high and others come back falsely low, not because your body’s actual levels have changed, but because the measurement system has been chemically disrupted. This effect has been documented with single doses of biotin ranging from 10 to 300 mg per day, commonly found in over-the-counter hair and nail supplements.
Which Tests Are Affected, And What False Results Can Mean
The clinical commentary, authored by researchers at Ohio State University and Virginia Commonwealth University, lists an extensive range of laboratory tests that biotin can distort. For cancer patients specifically, the consequences are serious:
Thyroid markers (TSH, T3, T4, thyroglobulin): Biotin can cause falsely low TSH levels in sandwich assays. A falsely low TSH can be misinterpreted as hyperthyroidism, potentially triggering unnecessary treatment or misguiding clinical decisions during immunotherapy, where thyroid function is actively monitored as an indicator of immune-related side effects.
Prostate-Specific Antigen (PSA): This is the primary blood marker used to detect prostate cancer recurrence after treatment. Biotin can produce falsely low PSA results in sandwich assays, meaning that a rising PSA, which would ordinarily signal recurrence, could appear normal on paper. A prostate cancer survivor taking biotin supplements could have their recurrence masked entirely.
Estradiol: In competitive immunoassays, biotin produces falsely elevated estradiol readings. For postmenopausal women with hormone-receptor-positive breast cancer, elevated estradiol is a key consideration in deciding when to initiate endocrine therapy treatments like aromatase inhibitors that suppress estrogen to slow cancer growth. A falsely elevated estradiol reading could delay starting this potentially life-saving therapy.
Other affected markers include testosterone, ferritin, progesterone, parathyroid hormone, luteinizing hormone, follicle-stimulating hormone, and dehydroepiandrosterone sulfate (DHEA-S), all of which are relevant to specific cancer types and treatment monitoring.
The range of cancers potentially affected by these distorted results spans thyroid, breast, endometrial, ovarian, germ cell, paraneoplastic, and prostate cancers.
Does Biotin Actually Grow Hair? The Evidence Is Weak
While the risks of biotin supplementation in cancer patients are medically documented, it is equally important to acknowledge that the claimed benefits are not well supported.
Biotin supplementation can genuinely help patients with a diagnosed vitamin B7 deficiency, a rare condition. For everyone else, including cancer patients experiencing chemotherapy-related hair loss, the evidence is remarkably thin. At the time this paper was published, only one clinical trial examined biotin supplementation for common hair loss and nail disorders. That trial did show some self-reported improvements in hair shedding, strength, and brightness, but it was conducted at a single institution, had a small sample size, and relied heavily on subjective questionnaire responses rather than objective clinical measurements.
The American Academy of Dermatology has formally agreed that biotin supplementation should not be used as a primary treatment for hair or nail regrowth. The social media popularity of biotin, driven by influencer content, glossy packaging, and testimonials, has significantly outrun the science.
What Actually Works: Topical Minoxidil
For cancer patients experiencing hair loss, there is a better-evidenced alternative that is also widely available and affordable: topical minoxidil.
Minoxidil works by prolonging the growth phase of hair follicles and increasing blood flow to the scalp. Importantly, it has no known contraindications in oncology patients and minimal side effects. Over-the-counter formulations cost approximately $20–22 USD per 60 mL bottle, making them comparable in price to biotin supplements.
In a randomized controlled trial, 87.5% of cancer patients using 5% topical minoxidil experienced significant improvement in hair regrowth after chemotherapy, compared with 55% in the placebo group. That is a meaningful clinical difference supported by proper trial methodology.
When the choice is between an intervention with strong trial evidence and no interference with cancer monitoring versus one with weak evidence and documented risks to diagnostic accuracy, the clinical recommendation is clear.
What Patients Should Know Before Taking Biotin
If you are currently undergoing cancer treatment or are in active monitoring after treatment, and you are taking or considering biotin supplements, here is what matters most:
Tell your oncologist. Only 6% of patients in a recent survey mentioned supplement use to their doctor. This number needs to change. Supplement use, including biotin in any form, including products like Nutrafol and Viviscal that contain biotin as an ingredient, is medically relevant information for anyone whose cancer monitoring relies on blood tests.
High-dose biotin requires a washout period. If you are taking high-dose biotin (above 100 mg per day), clinical guidelines recommend stopping supplementation for at least two to three days before any blood draw to allow the excess biotin to clear from your system and minimize interference with test results.
Biotin does not cause cancer recurrence or progression. The authors of this paper are explicit: there is no peer-reviewed evidence that biotin increases cancer risk or accelerates tumor growth. The concern is specifically about diagnostic accuracy, getting accurate readings from the blood tests that guide your care.
Consider alternatives. If hair regrowth during or after chemotherapy is a priority, ask your oncologist or dermatologist about topical minoxidil, which has stronger clinical evidence and does not interfere with cancer monitoring.
The Bigger Picture: Supplement Safety in Cancer Care
This paper is part of a broader conversation in oncology about the gap between how patients experience cancer in online communities, social media groups, and supplement aisles and the clinical risks that doctors need to communicate more proactively.
Hair loss during cancer treatment is not a vanity concern. It is a genuine source of psychological distress that affects quality of life, self-image, and how patients relate to their diagnosis. Patients deserve honest information about what actually helps, and they deserve to know when something that seems helpful could make their cancer harder to monitor accurately.
The solution is not to tell patients to simply accept hair loss and move on. It is to open the conversation and to point patients toward options that are both effective and safe.
If you are a cancer patient using biotin supplements or thinking about starting them, bring it up at your next appointment. The conversation is worth having.
References:
Mager, L., Ueltschi, O., Rose, L., & Dulmage, B. (2025). Biotin supplements for hair and nail regrowth: A caution for oncologists. JCO Oncology Practice. https://doi.org/10.1200/OP-25-00693